Literature DB >> 12682220

Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells.

Christian Mottet1, Holm H Uhlig, Fiona Powrie.   

Abstract

CD4(+)CD25(+) regulatory T cells have been shown to prevent T cell-mediated immune pathology; however, their ability to ameliorate established inflammation has not been tested. Using the CD4(+)CD45RB(high) T cell transfer model of inflammatory bowel disease, we show that CD4(+)CD25(+) but not CD4(+)CD25(-)CD45RB(low) T cells are able to cure intestinal inflammation. Transfer of CD4(+)CD25(+) T cells into mice with colitis led to resolution of the lamina propria infiltrate in the intestine and reappearance of normal intestinal architecture. CD4(+)CD25(+) T cells were found to proliferate in the mesenteric lymph nodes and inflamed colon. They were located between clusters of CD11c(+) cells and pathogenic T cells and found to be in contact with both cell types. These studies suggest that manipulation of CD4(+)CD25(+) T cells may be beneficial in the treatment of chronic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682220     DOI: 10.4049/jimmunol.170.8.3939

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  355 in total

1.  Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.

Authors:  Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso
Journal:  Adv Healthc Mater       Date:  2020-06-29       Impact factor: 9.933

2.  Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease.

Authors:  Silke Paust; Linrong Lu; Nami McCarty; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-02       Impact factor: 11.205

Review 3.  CD4+ CD25+ Treg: divide and rule?

Authors:  Lucy S K Walker
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

4.  Necrotising enterocolitis is characterised by disrupted immune regulation and diminished mucosal regulatory (FOXP3)/effector (CD4, CD8) T cell ratios.

Authors:  Jörn-Hendrik Weitkamp; Tatsuki Koyama; Michael T Rock; Hernan Correa; Jeremy A Goettel; Pranathi Matta; Kyra Oswald-Richter; Michael J Rosen; Brian G Engelhardt; Daniel J Moore; D Brent Polk
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

Review 5.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

6.  DCAF1 regulates Treg senescence via the ROS axis during immunological aging.

Authors:  Zengli Guo; Gang Wang; Bing Wu; Wei-Chun Chou; Liang Cheng; Chenlin Zhou; Jitong Lou; Di Wu; Lishan Su; Junnian Zheng; Jenny P-Y Ting; Yisong Y Wan
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

7.  High-fat diet modulates non-CD1d-restricted natural killer T cells and regulatory T cells in mouse colon and exacerbates experimental colitis.

Authors:  X Ma; M Torbenson; A R A Hamad; M J Soloski; Z Li
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

8.  CD4+CD25+ regulatory T cells have divergent effects on intestinal inflammation in IL-10 gene-deficient mice.

Authors:  Beate C Sydora; Sarah M MacFarlane; Michele M Tavernini; Jason S G Doyle; Richard N Fedorak
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

Review 9.  Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages.

Authors:  B Kelsall
Journal:  Mucosal Immunol       Date:  2008-09-17       Impact factor: 7.313

10.  Cutting edge: IFN-γR signaling in non-T cell targets regulates T cell-mediated intestinal inflammation through multiple mechanisms.

Authors:  Jeong-su Do; Kewal Asosingh; William M Baldwin; Booki Min
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.